Loading
EP0062 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at Androgen receptor.
EP0062 is a small-molecule drug developed by Ellipses Pharma. Its target is Androgen receptor. ClinicalTrials.gov describes the intervention as: EP0062 is an orally administered investigational selective androgen receptor modulator (SARM). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in HR-positive / HER2-negative breast cancer. The largest, NCT05573126, plans to enrol 95 participants with primary completion expected 2028-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small-molecule drug directed at Androgen receptor, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to Androgen receptor.
1.EP0062 slips into a pocket on Androgen receptor.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EP0062" OR ABSTRACT:"EP0062") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EP0062, not a curated reading list.
Shares Ellipses Pharma and the tag pipeline.
Shares Ellipses Pharma and the tag pipeline.
Shares Ellipses Pharma and the tag pipeline.
Shares Androgen receptor and the tag pipeline.
Shares Androgen receptor and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Androgen receptor and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.